Uncategorized Archives - BioProcess InternationalBioProcess International

Maxion awarded grant to advance antibody platform

Maxion Therapeutics has been awarded £2 million ($2.4 million) from Innovate UK to develop ion channel antibodies for autoimmune diseases. The grant from Innovate UK is part of its £25 million ($31 million) Biomedical Catalyst fund, which aims to support UK-registered businesses to advance solutions to address health and healthcare challenges. Maxion, a Cambridge, UK based firm, will use the funding to support and develop its KnotBody platform for autoimmune diseases with high unmet clinical need. “KnotBody platform utilizes a…

Forge Bio bags $90m funding to expand CGT capabilities

by Millie Nelson

CDMO Forge Biologics has completed a $90 million Series C financing round, which will be used to expand its technologies, manufacturing systems, and cell lines. The gene therapy contract development manufacturing organization (CDMO) Forge Bio has raised $90 million with finances led by Aisling Capital, Drive Capital, and an undisclosed strategic investor. According to the CDMO, it will expand the number of its service offerings available to customers in order to scale its gene therapy programs from research to clinical…

IVT Network Podcast Archive

by IVT Network

Journal of Validation Technology 2022 The EU GMP Annex1 Revision 2022 Implementation Laboratory Review Process and Its Impact on Compliance Data Integrity and Integrating Automation Risk Revolution: ICH Q9 Revision, Is it Enough? The Quality Control Response to COVID Disruption in Labs The New Norm for Life Sciences Talent Evolution 2021 Paper Versus Electronic Records Ruggedness of Visible Residue Limits for Cleaning Validation Cognitive Biases in Strategy and Execution Fuzzy Logic, Risk Management, and Critical Thinking in Pharmaceuticals. Integrate Risk…

IVT-JVT Journal Archive

by IVT Network

Journal of Validation Technology Archive Vol. 28, Issue 2, Apr 2022 Calculations Roundtable #1: Invitation to Participate Authors: Brad Bartels, Paula L. Pluta Compounding Forum #1: Invitation to Participate Authors: Nishant B. Thakar, Paula L. Pluta Vol. 28, Issue 1, Feb 2022 Shadows of Missed Opportunities In Learning Excellence Author: Lori Richter SR #3. Data Variance, Central Tendency, and Measurement Calculations (Continued) Author: Alan M Golden VCS #10. Cleaning Validation Equipment Sampling Locations Author: Paul L. Pluta Mycoplasma and Cell…

IVT Journal Archive

by IVT Network

IVT Network Archive The Journal of Validation Technology, The Journal of GXP Compliance, and the IVT Network have served proudly for nearly 30 years as a global knowledge base for validation and compliance professionals in FDA-regulated industries. To make peer-reviewed validation resources available to the broader biomanufacturing community, the IVT Network is joining sister publication BioProcess International. Starting in July 2022, articles from the past two years of JVT and GXP can be accessed here on the BioProcess International website.…

IVT – GXP Journal Archive

by IVT Network

Journal of GXP Compliance Archive Vol. 26, Issue 2, Mar 2022 Avoiding Errors With The Batch Release Process: Best Practice CGMPs Author: Tim Sandle Medication Safety – Pharma Industry Considerations Questions From Readers #2 Author: Paul L. Pluta Calculations Roundtable #1: Invitation To Participate; Nishant B. Thakar Author: Paul L. Pluta FDA Seek Comments on Quality System (QS) Regulations Amendments Author: IVT Staff Quality Plans for Pharmaceuticals and Healthcare: Checking the Maturity of Your Quality System Author: Tim Sandle Critical…

Univercells partners with CBET to prep students for CGT space

by Millie Nelson

The partnership will see Univercells Technologies provide support to prepare Albany College of Pharmacy and Health Sciences (ACPHS) students for careers in cell and gene therapy. APHS’ Stack Family Center for Biopharmaceutical Education and Training (CBET) provides research and training solutions for the biopharmaceutical manufacturing space and is Univercells first US-based training partner. Under the terms of the deal, of which financial details have not been divulged, Belgian-based firm Univercells is set to give on-site access and training on cutting…

For resins, supply chain resilience is key, says Purolite

by Millie Nelson

As the demand for resins rises in the bioproduction space, BioProcess Insider spoke to Hans Johansson, global applications director at Purolite to find out the challenges they face and what they are doing to overcome them. BioProcess Insider (BI): Let’s get right back to basics. What are bioprocess resins and how are they made? Hans Johansson (HJ): Depending on the molecule requiring purification, chromatography resins are typically leveraged to optimize purity and yield. Chromatography in bioprocessing aims to accomplish three…

List forks out $125m+ for microbiome Indiana plant

by Millie Nelson

List Therapeutics will increase manufacturing capacity for live biotherapeutics products (LBPs) with its $125+ million investment in Indiana, US. List Therapeutics, whose parent company is South Korean firm Genome & Company, will invest in the city of Fishers, Indiana to build a 110,000 square-foot outsourcing facility. According to the firm, the facility will be commissioned by the end of 2023 and will be located at the Fishers Life Science and Innovation Park. The plant expands List’s offering of end-to-end manufacturing…

HPNE to hire 150+ to support Rhode Island facility

by Millie Nelson

High Purity New England (HPNE) will hire more than 150 employees as part of a larger strategic plan for the firm. HPNE, a supplier of equipment and solutions for the biopharmaceutical sector, will begin to immediately hire 150+ employees in what the company is dubbing as a “substantial hiring push” as it prepares to open its facility in early December. The firm has invested more than $10 million at its plant in Smithfield, Rhode Island – just 50 minutes south…